Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are generally well enough to carry out daily activities with little to no limitation (measured by a standard scale called ECOG, scoring 0 or 1)
• People diagnosed with a type of B-cell lymphoma (a blood cancer) that has come back or stopped responding to treatment, and whose cancer cells test positive for proteins called CD20 and/or CD22
• People with specific subtypes of B-cell lymphoma as defined by the World Health Organization (WHO) — the exact subtypes that are eligible depend on which part of the trial a person is being considered for (confirm with trial site)
• People whose lymphoma has returned or stopped responding after at least 2 previous lines of treatment, which must have included specific types of treatment depending on their lymphoma subtype (confirm with trial site which prior treatments are required for each subtype)
• People whose lymphoma subtype has an approved CAR T-cell therapy available, who have already received it — or people who were unable to receive it for medical reasons such as difficulty collecting cells, inability to wait for the process, or having CD19-negative disease
• People considered at high risk of prolonged blood cell recovery who have their own stem cells stored and available before starting the treatment regimen

Who may not be able to join:

• People who have recently taken an experimental treatment (other than cell/gene therapies or certain antibody treatments) within 14 days or 5 half-lives before starting the trial regimen, whichever is shorter
• People who have recently received approved chemotherapy, biological therapy (other than certain antibodies), or targeted therapy within 14 days or 5 half-lives before starting the trial regimen, whichever is shorter
• People who have had more than 4 previous lines of treatment for their lymphoma
• People who received certain antibody-based therapies within 30 days before starting the trial regimen
• People who received immune-stimulating treatments within 3 half-lives before starting the trial regimen
• People who received any cell or gene therapy within 6 months before starting the trial regimen
• People who have previously received cell or gene therapy that targeted both CD20 and CD22 at the same time
• People who received their own stem cell transplant within 6 weeks before starting the trial regimen
• People who received a donor stem cell transplant within 3 months, or donor immune cells within 6 weeks, before starting the trial regimen
• People who have active graft-versus-host disease (a complication from donor transplants), or who have not been off all immune-suppressing medications for at least 6 weeks
• People who received radiation therapy within 8 weeks before starting the trial regimen (except limited palliative radiation to specific areas)
• People with lymphoma that is currently active in the brain or spinal cord, or that has previously spread there
• People with an active and significant disorder affecting the brain or nervous system
• People taking more than 20 mg per day of prednisone (a steroid) or an equivalent dose of another steroid
• People with a known active infection of any kind (bacterial, viral, fungal, or other), or a reactivation of a previous infection
• People with a history of severe allergic reaction to a drug called alemtuzumab
• People who have developed antibodies that neutralise alemtuzumab
• People with an uncontrolled heart or blood vessel condition within the 3 months before joining
• People who currently need ongoing immune-suppressing treatment
• People who had major surgery within 28 days before starting the trial regimen
• People with another uncontrolled cancer diagnosed within the past 2 years (with the exception of certain early-stage skin cancers or early cervical cell changes)

Important: Always verify eligibility with the trial site directly before applying.